Metagenomi Therapeutics, Inc.
For the period ended Jun 30, 2026. Filed Aug 10, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 10, 2026
MGX$0.71-2.9%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Balance Sheets
(In thousands, except share and per share data)
| June 30, | December 31, | |
|---|---|---|
| 2026 | 2025 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $39,028 | $41,722 |
| Available-for-sale marketable securities | 81,636 | 119,077 |
| Accounts receivable | — | 305 |
| Prepaid expenses and other current assets | 3,804 | 4,434 |
| Total current assets | 124,468 | 165,538 |
| Property and equipment, net | 9,896 | 12,288 |
| Long-term investments | 2,154 | 2,154 |
| Operating lease right-of-use assets | 31,772 | 35,094 |
| Other assets | 1,018 | 836 |
| Restricted cash | 4,393 | 5,193 |
| Total assets | $173,701 | $221,103 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $2,603 | $1,489 |
| Accrued expenses and other current liabilities | 7,596 | 6,719 |
| Current portion of operating lease liabilities | 6,235 | 6,025 |
| Deferred revenue | 11,198 | 8,700 |
| Total current liabilities | 27,632 | 22,933 |
| Non-current portion of operating lease liabilities | 31,485 | 34,632 |
| Deferred revenue, non-current | — | 2,989 |
| Other non-current liabilities | 2,017 | 1,953 |
| Total liabilities | 61,134 | 62,507 |
| Commitments and contingencies (Note 8) | ||
| Stockholders’ equity: | ||
| Preferred stock: $0.0001 par value; 10,000,000 shares authorized and zero shares issued and outstanding | — | — |
| Common stock: $0.0001 par value; 500,000,000 shares authorized; 37,777,105 and 37,620,668 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively | 4 | 4 |
| Additional paid-in-capital | 474,096 | 469,202 |
| Accumulated other comprehensive income (loss) | (122) | 260 |
| Accumulated deficit | (361,411) | (310,870) |
| Total stockholders’ equity | 112,567 | 158,596 |
| Total liabilities and stockholders’ equity | $173,701 | $221,103 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.